CN114306297A - 蛋白酶体抑制剂及其用途 - Google Patents

蛋白酶体抑制剂及其用途 Download PDF

Info

Publication number
CN114306297A
CN114306297A CN202210020990.XA CN202210020990A CN114306297A CN 114306297 A CN114306297 A CN 114306297A CN 202210020990 A CN202210020990 A CN 202210020990A CN 114306297 A CN114306297 A CN 114306297A
Authority
CN
China
Prior art keywords
monocyclic
alkyl
bicyclic
group
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210020990.XA
Other languages
English (en)
Chinese (zh)
Inventor
林钢
C·纳桑
P·K·辛格
施磊
L·柯克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN114306297A publication Critical patent/CN114306297A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202210020990.XA 2015-10-15 2016-10-17 蛋白酶体抑制剂及其用途 Pending CN114306297A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562242139P 2015-10-15 2015-10-15
US62/242,139 2015-10-15
CN201680065296.2A CN108351169B (zh) 2015-10-15 2016-10-17 蛋白酶体抑制剂及其用途
PCT/US2016/057346 WO2017066763A1 (en) 2015-10-15 2016-10-17 Proteasome inhibitors and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680065296.2A Division CN108351169B (zh) 2015-10-15 2016-10-17 蛋白酶体抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN114306297A true CN114306297A (zh) 2022-04-12

Family

ID=58518357

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210020990.XA Pending CN114306297A (zh) 2015-10-15 2016-10-17 蛋白酶体抑制剂及其用途
CN201680065296.2A Active CN108351169B (zh) 2015-10-15 2016-10-17 蛋白酶体抑制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680065296.2A Active CN108351169B (zh) 2015-10-15 2016-10-17 蛋白酶体抑制剂及其用途

Country Status (7)

Country Link
US (2) US11066397B2 (https=)
EP (2) EP4006012A1 (https=)
JP (2) JP6970085B2 (https=)
KR (1) KR102764027B1 (https=)
CN (2) CN114306297A (https=)
ES (1) ES2905008T3 (https=)
WO (1) WO2017066763A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
CN107073069B (zh) 2014-08-18 2022-03-08 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
WO2017066763A1 (en) 2015-10-15 2017-04-20 Cornell University Proteasome inhibitors and uses thereof
US11357817B2 (en) * 2017-05-15 2022-06-14 The Regents Of The University Of California Immunoproteasome inhibitor
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11834515B2 (en) 2017-10-11 2023-12-05 Cornell University Macrocyclic compounds as proteasome inhibitors
EP3674288A1 (en) 2018-12-31 2020-07-01 MMV Medicines for Malaria Venture Pantothenamide analogues
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
EP4392037A4 (en) * 2021-08-27 2025-09-17 Boyce Thompson Institute For Plant Res Inc THERAPEUTIC COMPOSITIONS AND ASSOCIATED METHODS
EP4155296A1 (en) * 2021-09-24 2023-03-29 Lead Discovery Center GmbH Macrocyclic compounds as proteasome subunit beta type-5 inhibitors
WO2024182664A1 (en) * 2023-03-01 2024-09-06 Boyce Thompson Institute For Plant Research, Inc. Modified rna compositions and related methods
WO2026041079A1 (zh) * 2024-08-23 2026-02-26 江苏正大清江制药有限公司 肽环氧酮类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298785A (ja) * 2005-04-18 2006-11-02 Mitsui Chemicals Inc ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤
CN101506224A (zh) * 2006-06-19 2009-08-12 普罗特奥里克斯公司 蛋白酶体抑制用的肽环氧酮
CN102015673A (zh) * 2008-02-21 2011-04-13 耐克斯詹尼克斯医药有限公司 用作治疗剂的大环前药化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223629B (https=) 1992-03-06 1994-05-11 Hoffmann La Roche
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
PE32799A1 (es) 1996-12-25 1999-04-09 Agrogene Ltd Nuevo derivado del acido aminobutirico para la proteccion de enfermedades fungosas
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US7244743B2 (en) 2002-06-05 2007-07-17 Solvay Pharmaceuticals Gmbh Non-peptidic BRS-3 agonists
EP1547590A4 (en) 2002-09-13 2008-07-30 Oga Res Inc MELANIN EXTINGUISHER
TWI334868B (en) 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
US20070244153A1 (en) 2004-07-21 2007-10-18 Mitsui Chemicals, Inc. Diamine Derivative, Process of Preparation Thereof, and Fungicide Comprising Diamine Derivative as an Active Ingredient
PE20060621A1 (es) 2004-09-07 2006-06-29 Smithkline Beecham Corp 1,3-diaminas aciclicas como agonistas de los receptores del canal trpv4
WO2006065826A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
EP1863513A2 (en) 2005-03-11 2007-12-12 The University of North Carolina at Chapel Hill Potent and specific immunoproteasome inhibitors
US20090227601A1 (en) 2005-12-07 2009-09-10 Amgen Inc. Bradykinin 1 Receptor Antagonists
WO2007083394A1 (ja) * 2006-01-19 2007-07-26 Mitsui Chemicals, Inc. ジアミン誘導体を含む有害生物防除組成物
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
EP2192108B1 (en) 2007-09-11 2013-03-27 Tokyo University Of Science Educational Foundation Administrative Organization Novel dihydronaphthalene compound and use thereof
WO2009051581A1 (en) 2007-10-16 2009-04-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
EP2487152A1 (en) 2010-11-17 2012-08-15 UCB Pharma GmbH Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
US20140315786A1 (en) * 2011-03-18 2014-10-23 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
CN102807601B (zh) 2011-06-03 2014-02-26 首都医科大学 氨基酰-色氨酰-5-甲氧色胺及其制备方法和应用
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
JP2014091731A (ja) 2012-11-06 2014-05-19 Kobe Gakuin 新規ソマトスタチン由来ペプチド化合物並びに該化合物を含むｄｎａポリメラーゼ阻害剤、抗癌剤及びアポトーシス誘導剤。
JP6067878B2 (ja) 2012-12-21 2017-01-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オキシトシンアゴニストとしてのペプチド
WO2015076359A1 (ja) * 2013-11-21 2015-05-28 国立大学法人北海道大学 プロテアソーム阻害性化合物
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
CN107073069B (zh) 2014-08-18 2022-03-08 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
WO2017066763A1 (en) 2015-10-15 2017-04-20 Cornell University Proteasome inhibitors and uses thereof
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298785A (ja) * 2005-04-18 2006-11-02 Mitsui Chemicals Inc ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤
CN101506224A (zh) * 2006-06-19 2009-08-12 普罗特奥里克斯公司 蛋白酶体抑制用的肽环氧酮
CN102015673A (zh) * 2008-02-21 2011-04-13 耐克斯詹尼克斯医药有限公司 用作治疗剂的大环前药化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
牟科，等: "蛋白酶体抑制剂的研究进展", 国际药学研究杂志, vol. 36, no. 05, 15 October 2009 (2009-10-15), pages 348 - 354 *

Also Published As

Publication number Publication date
WO2017066763A1 (en) 2017-04-20
KR102764027B1 (ko) 2025-02-07
US20180282317A1 (en) 2018-10-04
CN108351169A (zh) 2018-07-31
ES2905008T3 (es) 2022-04-06
US20210171514A1 (en) 2021-06-10
EP3362754A1 (en) 2018-08-22
JP6970085B2 (ja) 2021-11-24
JP7379441B2 (ja) 2023-11-14
JP2018536635A (ja) 2018-12-13
EP3362754B1 (en) 2021-12-22
JP2022023934A (ja) 2022-02-08
US11629141B2 (en) 2023-04-18
EP4006012A1 (en) 2022-06-01
KR20180064427A (ko) 2018-06-14
EP3362754A4 (en) 2019-04-24
US11066397B2 (en) 2021-07-20
CN108351169B (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
US11629141B2 (en) Proteasome inhibitors and uses thereof
CN104159893B (zh) 哌啶化合物或其盐
TW201102389A (en) Fused pyrroloprydine derivatives
AU2007281747A1 (en) Indole compounds
US9988421B2 (en) Dipeptides as inhibitors of human immunoproteasomes
US8993523B2 (en) Dimeric IAP inhibitors
US11732005B2 (en) Peptidomimetic proteasome inhibitors
CN104945470B (zh) 杂环构建的三肽环氧酮类化合物及制备和应用
BR112014003146B1 (pt) 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com homopiperidinila antibacterianas, composição farmacêutica compreendendo os referidos composto e processos para preparação destes
US12473331B2 (en) Macrocyclic compounds as proteasome inhibitors
CN114796207A (zh) 作为人免疫蛋白酶体的抑制剂的二肽模拟物
WO2022159581A9 (en) Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease
TWI905781B (zh) 脯胺醯羥化酶抑制劑及其用途
WO2018213263A1 (en) Immunoproteasome inhibitor
WO2017193924A1 (zh) 螺三元环、螺五元环类肽脱甲酰基酶抑制剂及其在抗菌和抗肿瘤中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination